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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
asenapine or aripiprazole are more effective than a placebo for reducing episodes of
mania in children with bipolar I disorder.
Study Design: Review of two randomized control trials (RCTs) published in 2013 and
2015, and a flexible-dose, open-label, extension study published in 2016.
Data Sources: Each article used was published in English and found using PubMed
database. All articles were published in peer-reviewed journals.
Outcomes Measured: The clinical superiority of asenapine and aripiprazole were
measured by a change in baseline in the Young Mania Rating Scale (YMRS) total score.
A decrease in YMRS score indicates improved mania symptoms.
Results: Findling, et al. (2015) found that all studied doses of asenapine were more
effective than a placebo at reducing the baseline score of the Young Mania Rating Scale
(YMRS) [for 2.5 mg: -12.8 vs -9.6, p=0.008; for 5mg -14.9 vs -9.6, p <0.001; for 10mg: 15.8 vs -9.6, p <0.001]. Findling, et al. (2013) found that all doses of aripiprazole were
more effective than a placebo using the same YMRS change from baseline [for 10mg: 14.1 vs -8.2, p <0.001; for 30 mg: -14.9 vs -8.2, p <0.001]. This article also examined the
average time to withdrawal [for 10 mg 15.6 weeks vs 5.3, p <0.001; for 30 mg 9.5 vs 5.3,
p <0.05]. The Findling, et al. (2016) open-label, extension study found that there was a
greater mean change in baseline YMRS total scores in the placebo/asenapine population
(-13.0 at 26 weeks and -15.2 at 50 weeks), a 79.2% total population of patients that were
YMRS 50% responders, and 68.5% of all patients achieved YMRS remission.
Conclusions: Though each study reported an improvement of symptoms, the efficacy of
asenapine and aripiprazole over a placebo for the treatment of mania episodes in children
with bipolar I disorder cannot be determined due to the limitations in experimental design
and validity.
Key Words: Bipolar, bipolar I disorder, treatment, asenapine, aripiprazole, children,
mania episodes, placebo
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INTRODUCTION
Bipolar disorder is the sixth leading cause of disability, affecting nearly 6 million people
nationwide.1 These patients are notorious for extreme changes in mood, affect, and behavior.
There are two subclasses of bipolar disorder. Bipolar I disorder (BP1) is defined by the presence
of manic episodes, including: recklessness, insomnia, grandiose thoughts, aggression, heightened
irritability, and elevated self-esteem.1 This manic state causes severe social and occupational
impairment and may even require hospitalization. BP1 can also display periods of depression1,
though it is not required for diagnosis. Bipolar II disorder is alternatively characterized by
depressive states and hypomania episodes. Hypomania consists of less severe manic symptoms
which do not require hospitalization.1 Children with bipolar disorder are particularly difficult to
diagnose and often undergo multiple trials of different medications before achieving mood
stabilization.2 This review evaluates two randomized control trials and one flexible-dose, openlabel, extension study to determine if asenapine or aripiprazole are more effective than a placebo
in reducing mania episodes in children with BP1.
The exact cause of bipolar disorder is unknown, but there is certainly a genetic
component. Data show that two-thirds of those diagnosed with bipolar have at least one family
relative with unipolar or bipolar depression.1 Furthermore, children with one parent diagnosed
with bipolar disorder are at a 15-30% increased risk of developing it, and children with two
parents diagnosed have a 50-75% increased risk.1 Bipolar disorders are not the most common
psychological disorder encountered in medical practice, but its symptoms are debilitating and
result in severe financial and emotional disruption.
While recent data are unavailable, in 1991, the estimated total of direct medical costs
associated with bipolar disorder was $7.6 billion.3 More recent data from insurance claims
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between 1998 and 2000 demonstrated that a single patient with bipolar spends between $7,200
and $12,100 per year on care, 15% of which goes towards prescriptions alone.4 It is also
important to note that the real cost of this illness must take into account the loss of productivity
and detrimental impact to personal and professional relationships over time.
The emotional and behavioral swings indicating BP1 can present to behavioral health,
family medicine, or emergency medicine providers for initial diagnosis and/or treatment. As
such, it is important for all physician assistants to understand the medical management of this
disorder. The current gold standard of treatment is combination management with a mood
stabilizer (such as lithium), an antidepressant (such as Bupropion), and adjunctive
psychotherapy. Antipsychotics are also added to treat acute mania episodes. Typical
antipsychotics (such as chloropromazine) carry a large number of side effects, including:
movement disorders, neuroleptic malignant syndrome, ophthalmologic problems, dermatologic
problems, and increased seizure risk. Atypical antipsychotics (such as asenapine and
aripiprazole) on the other hand, have fewer side effects and are therefore better tolerated in
bipolar patients. The atypical class is currently considered first line treatment for acute mania in
bipolar adults. It is important to study their efficacy in children so this population of patients can
also experience fewer side effects with pharmacological management of their disease.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not asenapine or
aripiprazole are more effective than a placebo for reducing episodes of mania in children with
bipolar I disorder.
METHODS
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This review examines two double-blinded, randomized control trials (RCTs) and one
flexible-dose, open-label, extension study that examined a population of children aged 10-17
years old diagnosed with bipolar I disorder with either manic or mixed episodes. The
interventions under study were the use of asenapine or aripiprazole as compared to a placebo.
Though the studies used different medications, the intent was to determine the efficacy of either
drug as compared to a placebo. This outcome was measured by a change from baseline using the
Young Mania Rating Scale (YMRS) score and time to withdrawal.
Articles for this review were discovered by applying keywords such as: bipolar disorder,
asenapine, aripiprazole, treatment, children, and mania. All articles utilized were published in
English, in peer-reviewed journals, and found via searches on the PubMed database. Article
selection was further refined based on relevance to the stated clinical question, and whether or
not they included patient-oriented outcomes (Table 1). Inclusion criteria for this review
contained at least two randomized control trials published after 2007, a study population of
children, and a placebo comparison group. Patients over 18 years old, patients on multiple drug
regimens for mania control, and drug-to-drug comparison studies were excluded. The summary
statistics reported were mean changes from baseline, confidence intervals, p-values, and
ANCOVAs.
Table 1: Demographics & Characteristics of Included Studies
Study
Findling
RL,
Landbloom
RL,
Szegedi
A
(2015)5

Type
RCT

# of
Pts
403

Age
(yrs)
10-17

Inclusion
Criteria
Primary
diagnosis of
BP1 with
associated
manic or mixed
episodes, a
total YMRS >
20 at baseline,
and a guardian
living with the

Exclusion Criteria
Patients with a pervasive
development disorder or other
mood disorder, prohibited
contaminant medication, or an
uncontrolled, unstable
clinically significant medical
condition

W/D
53

Intervention
s
Patients
taking
asenapine
(2.5mg, 5mg,
or 10 mg)
BID vs
matching
placebo
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Findling
RL,
Correll
CU
(2013)6

RCT

210

10-17

Findling
RL,
Landbloom,
RL
(2016)7

Open-label,
flexibledose,
extension
study

321

10-18

child who was
able to ensure
adherence
Primary
diagnosis of
BP1 with
current manic
or mixed
episodes,
confirmation of
diagnosis by a
second
clinician, total
YMRS > 20 at
baseline
Primary
diagnosis of
BP1 with a
current manic
or mixed
episodes, total
YMRS > 20 at
baseline,
informed
consent from a
legal guardian

Article states that “baseline
characteristics have been
stated previously,” but
referenced information could
not be obtained

86

Patients
taking 10mg
or 30mg /day
of
aripiprazole
vs matching
placebo for
26 weeks

Patients with a pervasive
development disorder, or other
mood disorder, mental
retardation, use of prohibited
contaminant medications,
pregnancy, HIV, high risk of
self-harm or harm to others,
involuntary inpatient
commitment, or poor
adherence to other medications

181

Patients
taking openlabel doses of
asenapine

OUTCOMES MEASURED
The outcomes measured were the clinical superiorities of asenapine or aripiprazole as
compared to a matched placebo. Drug efficacy was measured by a change in baseline in YMRS
total score. The YMRS is an eleven-item, clinician-rated scale to assess the severity and
symptoms of mania episodes.5-7 Values can range from 0 (all symptoms are absent) to 60 (all
symptoms are extreme). A decrease in YMRS score from baseline indicates improved mania
symptoms.5-7 The three articles all present data as continuous and could not be converted to
dichotomous. The articles by Findling RL, et al. (2013)6 and Findling RL, et al. (2016)7
additionally give long-term efficacy results for asenapine in terms of time to failure to maintain
effect. Findling RL, et al. (2016)7 also assesses the total number of YMRS 50% responders and
remitters.
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RESULTS
The two randomized control trials used in this review aim to determine the effectiveness
of either asenapine or aripiprazole as compared to a placebo in controlling mania episodes in
children. The open-label, extension study determines the long-term effectiveness of asenapine in
the same population. Efficacy was evaluated by determining the mean change from baseline
scores of clinician-rated, interview-based surveys. The inclusion and exclusion criteria of all
three articles (Table 1) are comparable, and all patients that began each trial are accounted for
within that respective article’s results.
Findling RL, et al. (2015)5 conducted a double-blinded, randomized control trial
consisting of 403 patients between the ages of 10-17 years old diagnosed with BP1 with current
manic or mixed episodes. Before acceptance into the medication phase of the trial, each patient
was required to undergo a 2- to 14-day screening/tapering period to ensure there were no
contaminant medications present.5 Study participants were then randomized and treated with
asenapine at 2.5 mg, 5 mg, or 10 mg BID, or a placebo BID for 3 weeks.5 The 2.5 mg dose was
administered from day 1; the 5 mg dose group was administered as 2.5 mg BID for 3 days, then
titrated up to 5 mg BID thereafter; and the 10 mg dose group was administered as 2.5 mg BID
for 3 days, then 5 mg BID for 3 days, then 10 mg BID thereafter.5
The efficacy of asenapine was measured by determining the YMRS score changes.
Participants were measured at baseline and day 21. The raw data for each participant’s YMRS
score report was not included in the published results of this study, but the overall mean change
from baseline and p-value for each trial group was provided (Table 2). Since the YMRS scores
are more negative for all 3 doses of asenapine than the placebo group, these data indicate that
asenapine is superior to a placebo in reducing mania symptoms.5 P-values less than 0.05 indicate
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that the decrease in mania symptoms within each trial group were statistically significant and
likely a result of the administration of asenapine.
Table 2: Mean Change in YMRS Total Score of the Findling RL, et al. (2015)5 RCT
Treatment Group
Placebo
2.5 mg of Asenapine
5 mg of Asenapine
10 mg of Asenapine

Mean Change in YMRS
-9.6
-12.8
-14.9
-15.8

p-value
p=0.008
p<0.001
p<0.001

A 30-week, randomized, double-blind, placebo-controlled trial by Findling RL, et al.
(2013)6 enrolled 210 patients diagnosed with BP1 between the ages of 10-17 years old that
successfully completed a four-week aripiprazole acute treatment phase. These subjects were
randomized in the acute-phase into three groups: 10 mg/day of aripiprazole, 30 mg/day of
aripiprazole, and a matching placebo once daily for a 26-week extension study.6 For safety,
these doses were titrated up slowly in the acute phase of the trial, then continued at the target
dose for the remaining 26 weeks.
Efficacy of aripiprazole was determined in two ways. The first method examined the
overall time to withdrawal of the drug. The longer the time to withdrawal, the more effective the
treatment group is at controlling symptoms of mania.6 Out of the original 296 patients that
completed the acute-phase, only 210 entered the extended-phase. Overall, only 32.4% of subjects
competed the 30-week study.6 The most common reason for withdrawal was lack of efficacy
(22.7% for the 10 mg dose, 14.1% for the 30 mg dose, and 48.4% for the placebo).6 Table 3 lists
the average time to discontinuation of each drug group. These results show that the longest time
to discontinuation was for the subjects taking the 10 mg/day dose of aripiprazole. As mentioned
above, this increased time to withdrawal indicates a longer period of efficacy for the 10 mg
aripiprazole group. Even though, the 95% confidence intervals (CI) and p-values (<0.05)
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statistically support this claim, no other analyses were performed to assess if confounding
variables are present within this data. As such, these results should be interpreted with caution.
Table 3: Median Time to Discontinuation of the Findling RL, et al. (2013)6 RCT
Treatment Group
Placebo
Aripiprazole 10
mg/day
Aripiprazole 30
mg/day

Median Time to W/D
(weeks)
5.3
15.6

95% Confidence Interval
(weeks)
4.7-6.9
8.1-24.3

p-value
p<0.001

9.5

6.1-13.9

p<0.05

Utilizing the mean change from baseline in YMRS total scores from week 1 through
week 30, the efficacy of aripiprazole was further analyzed. Table 4 shows the mean change in
baseline of YMRS total scores. The larger negative scores indicate that both doses of
aripiprazole were superior to the placebo in reducing episodes of mania in children. Since the pvalues are less than 0.05, the data are considered statistically significant, and therefore not due to
random chance. Additionally, these values were analyzed using an analysis of covariance
(ANCOVA) model that allowed researchers to control for continuous variables that have nothing
to do with the treatment interventions, but might influence the outcome.
Table 4: Mean Change in YMRS Total Score of the Findling RL, et al. (2013)6 RCT
Treatment Group
Placebo
Aripiprazole 10 mg/day
Aripiprazole 30 mg/day

Mean Change in YMRS
-8.2
-14.1
-14.9

p-value
p<0.001
p<0.001

Findling RL, et al. (2016)7 conducted a flexible-dose, open-label, 50-week extension
study to evaluate the long-term efficacy of asenapine for the treatment of manic episodes in
children aged 10-18 years old with BP1. In order to enroll into this study, participants were
required to complete an acute-phase and adhere to the exclusion/inclusion criteria listed in Table
1. In the acute-phase, patients were randomized into placebo, asenapine 2.5 mg, 5 mg, or 10 mg
BID groups for 3 weeks.7 Of the 350 patients who completed the acute-phase, 321 were included
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in the final analysis.7 The first day of the extension-study overlapped with the last day of the
acute-phase (day 21). In the extension-phase, all enrolled patients were given an open-label, fastdissolving, sublingual asenapine tablet at 2.5 mg BID on day 1. On day 4, patients were
increased to 5mg, then to 10 mg on day 7. For the remainder of the trial, patients were given
flexible dosing based on tolerability and symptomology.7
Efficacy of long-term asenapine administration was assessed in three ways. First, the
mean change from baseline in YMRS total scores was given, as seen in Table 5. These values
show that the greatest improvement in YMRS scores was the acute-phase placebo group who
began receiving asenapine at the beginning of the extension-phase (placebo/asenapine).
Table 5: Mean Change in YMRS Total Score of the Findling RL, et al. (2016)7 Extension-trial
Treatment Group
Placebo/Asenapine
Asenapine/Asenapine

Mean Change in YMRS at 26
Weeks
- 13.0
- 4.9

Mean Change in YMRS at 50
Weeks
-15.2
- 6.5

The second efficacy assessment reviewed the time to failure to maintain effect from
open-label baseline to any time point. This was defined as a <50% reduction from baseline in
YMRS total score during the extension-phase out of the participants who already achieved a 50%
reduction response during the acute-phase.7 Of the 141 patients who had at least a 50% mean
change from baseline in YMRS total score at the completion of the acute-phase, 46 patients
(32.6%) failed to maintain a decrease in mania symptoms.7 Since no CIs or p-values are reported
for either of these assessments, the statistical significance of this data is questionable.
Finally, the percentage of responders and remitters from baseline to endpoint were used
to determine efficacy. YMRS responders were defined as those who achieved a >50%
improvement in YMRS total score; and YMRS remitters were required to obtain a YMRS total
score <12.7 Out of the 149 responders at baseline, 118 (79.2%) were still responders, and 102 of
149 (68.5%) were remitters at the end of 26-weeks.7 There was no data reported for the 50-week
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end-date. The article reports that these percentages suggest a large proportion of patients
achieving clinically meaningful mania relief,7 but no p-values or other statistical support data are
given. Without support, these statements of drug efficacy are uncertain.
DISCUSSION
Although the study by Findling, et al. (2016) concluded that treatment with asenapine
provided long-term mania symptom relief in children with BP1, the lack of statistical analysis
leaves this claim unsupported. No other outliers were apparent in the remaining two articles.
Asenapine (brand name Saphris) and aripiprazole (brand name Abilify) are both atypical
antipsychotic drugs that work on dopamine (D) and serotonin (5-HT) receptors. Aripiprazole is a
quinolone antipsychotic that functions as a partial agonist at the D2 and the 5-HT1A receptors, and
as an antagonist at the 5-HT2A receptor.8 Asenapine is a dibenzo-oxepino pyrrole antipsychotic
with mixed serotonin-dopamine activity.9 Aripiprazole is available as a pre-filled syringe, an IM
injection that must be reconstituted with sterile water, an oral tablet, or a dissolving sublingual
tablet that can be taken with or without food.8 Asenapine is only available as a dissolvable
sublingual tablet that must be taken at least ten minutes before consuming any liquids or foods.9
There is no generic version of asenapine, and the cost is $21.94 per tablet.9 Since the
recommended dosing is one tablet taken twice a day, asenapine comes to a total of $1,316.40 per
month. Brand-name aripiprazole is even more expensive and ranges in price from $2,364.76 (per
single dose of a prefilled syringe) to $963.25 (for a 30-day supply of a 2 mg tablet).8
Fortunately, a generic version is now available and averages $24.17 for a 30-day supply.10
Medicare and most insurance companies cover both drugs.8,9
The FDA approved asenapine for use on August 13, 2009 and aripiprazole on June 1,
2012.8,9 Both drugs are now readily available on the US market and are used for the treatment of
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manic or mixed episodes of BP1, as well as schizophrenia in adults.8,9 Aripiprazole is also used
to treat major depressive disorder, Tourette’s disorder, and irritability associated with autistic
disorders.8 Both drugs are can be used off-label to reduce psychosis/agitation associated with
dementia.8,9 Asenapine and aripiprazole are both associated with a black box warning due to
adverse effects. These drugs increase mortality in elderly populations with dementia-related
psychosis.8,9 Aripiprazole has an additional black box warning for an increased risk of suicidal
thoughts in children.8 The side effects of both drugs are consistent with others in the atypical
antipsychotic class, including: weight gain, metabolic effects, extrapyramidal symptoms,
sedation, orthostatic hypotension, and QT prolongation.11
There were some limitations with this review due to an inadequate number of available
RCTs. An open-label extension trial was selected to complete this review since the majority of
the reported data were the results of the acute-phase, rather than the extension-phase. Upon
further investigation, it was noted that this study did not compare different doses of asenapine to
a control placebo, but rather examined the long-term affect of open-label asenapine dosing as
compared to an acute phase. The efficacy data reported within this article is unsupported and
therefore indeterminate. Additionally, the lack of RCTs made it difficult to select articles that
examined a similar timeframe. One study assessed the efficacy of a treatment drug in the shortterm, another study examines drug efficacy in the long-term, the yet another uses efficacy data
from an acute-phase trial to complete long-term analyses. Having three RCTs comparing similar
timeframes would allow for a more accurate assessment in regards to the proposed question.
Moreover, limitations within the studies themselves include issues with validity, blinding,
and sample size. The validity issues in were mentioned above, but the Findling, et al. (2016)
article also fails to blind both the participants and the administrators. This can lead to a bias
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affect in the experimental outcomes. Finally, the low completion rates in the Findling, et al.
(2013) and Findling, et al. (2016) studies (59% and 44.6%, respectively) limit the ability to draw
definitive conclusions due to a small sample size.
CONCLUSION
After reviewing the data from all three articles, it is inconclusive whether there is
statistically reinforced data to support the efficacy of either asenapine or aripiprazole over a
placebo for reducing mania episodes in children with bipolar I disorder. Even though the
Findling, et al. (2015) and Findling, et al. (2013) studies showed meaningful data that supports
the efficacy of both asenapine and aripiprazole, the short-term nature and small sample size
(respectively) of these trials leave the long-term benefits open for future research. Additionally,
the Findling, et al. (2016) study lacks a placebo-control group and statistically supported data
making it wholly unreliable. It should also be noted that all three articles in this review selected a
patient population using the criteria explained in the Diagnostic and Statistical Manual of Mental
Disorders, Version 4 (DSM-4).5-7 A more detailed criterion list for manic episode diagnosis has
since been updated in DSM-5.5-7 It is unclear how this update would affect the
inclusion/exclusion criteria in these studies; therefore, new research should be undertaken and
include the new diagnostic criteria. Finally, the placebo-controlled studies are of great value, but
they do not allow for a direct comparison of asenapine and aripiprazole efficacy. It would be
beneficial to undertake research that compares asenapine and aripiprazole to each other. A drugto-drug comparison analysis could discover which agent is the most successful in the pediatric
population. Overall, more research is necessary to determine if asenapine or aripiprazole is more
effective than a placebo in reducing mania in children with bipolar I disorder.
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